The "Diagnostic Odyssey" cannot be solved in a silo. It requires a radical convergence of frontline clinical care, deep-tech infrastructure, and patient-led advocacy. Regal Intel serves as the neutral, non-profit fiduciary connecting these critical pillars.
We are proud to collaborate with, integrate, and draw guidance from some of the world's leading academic medical centers, patient advocacy networks, and technology innovators.
Clinical & Academic Research Hubs:
To map the natural history of complex diseases, we partner with top-tier academic institutions to transform decades of clinical expertise into regulatory-grade evidence.
- University of Pittsburgh: Advancing rare disease research and transform retrospective deep-phenotypic data into regulatory-grade natural history models.
- PCORNet: Aligning with national clinical research networks and physiological data repositories to ensure our evidence generation meets the highest standards of interoperability and patient-centered ourcomes.
- PhysioNet: Integrating with the premier global repository of complex physiological signals. We leverage these expansive, clinical datasets to benchmark our biological velocity algorithms and mathematically validate our continuous-time disease models.
Patient Advocacy & Rare Disease Networks
The patient is our North Star. We work directly with foundation leaders to ensure that their community registries are protected, structured, and ready for therapeutic development.
- Cure GM1 Foundation: Strategic collaboration to build prospective, BIMO-ready Natural History models for GM1 Gangliosidosis.
- National Organization for Rare Disorders (NORD): Active engagement to empower patient communities and standardize decentralized phenotypic data mapping.
- Orphanet: Aligning with the definitive global reference portal for rare diseases and orphan drugs. By mapping our diagnostic intelligence to standardized ORPHA nomenclature, we ensure our synthetic evidence is universally recognized by international regulators and the global research community.
Sovereign Infrastructure & Technology Ecosystem
To guarantee "Zero Exfiltration" and execute our "Code-to-Data" architecture, we encourage building upon the most secure, advanced computational platforms in the world.
- NVIDIA: Utilizing world-class GPU infrastructure and edge-computing frameworks to power our decentralized AI models securely.
- Google Cloud (BAA Compliant): Leveraging HIPAA-compliant, business-associate-secured infrastructure for the encrypted orchestration of our consortium networks.
Strategic Advisory Board
Our consortium is guided by a multidisciplinary board of industry veterans, bridging the gap between clinical genetics, patient advocacy, and global pharmaceutical commercialization.
- Sanjay Ahuja, Ph.D.
Chief Science Officer
- Dave DeBord
Chief Operating Officer, Royal Chemical
- James Metzger
VP & GM, ThermoFisher Scientific
- Vishal Prasad
President & Founder, Mareana
- Suresh Raman
VP of Digital, Johnson & Johnson
- Jerry Vockley, MD, Ph.D.
Chief of Medical Genetics, University of Pittsburgh Medical Center (UPMC) / Children's Hospital
- Christine Waggoner
President & Founder, Cure GM1 Foundation